Research News for 2010
-
Experimental Iniparib Shows Promise in Treating Advanced-Stage Disease
A small, early study suggests that some advanced-stage cancers may respond to an experimental combination of iniparib and Camptosar.
-
Real World Survival Stats for Avastin Mirror Clinical Results
Analysis shows that the real world survival statistics of women diagnosed with metastatic breast cancer and treated with chemotherapy and Avastin were similar to survival statistics of women in clinical trials looking at the same combination.
-
Pathologic Complete Response to Treatment Before Surgery Linked to Better Prognosis
Research found that women who got neoadjuvant treatment and had a complete pathologic response were less likely to have the cancer come back compared to women who didn't have a complete pathologic response.
-
Prophylactic Brain Radiation Therapy Doesn’t Seem to Cause Cognitive Problems
A small, early study found that preventive cranial radiation in addition to Herceptin and chemotherapy didn't cause more or different cognitive problems than Herceptin and chemotherapy alone in women diagnosed with HER2-positive metastatic breast cancer.
-
Xgeva Better Than Zometa at Reducing Risk of Breast Cancer Bone Problems
Research has found that Xgeva (chemical name: denosumab), a new targeted therapy medicine, is better than Zometa at lengthening the time before bone complications develop in women diagnosed with breast cancer that has spread to the bones.
-
Herceptin More Effective Than Tykerb When Given Before Surgery
Research suggests that Herceptin is more effective than Tykerb in a neoadjuvant regimen for early-stage or locally-advanced HER2-positive breast cancer.
-
Herceptin-Tykerb-Chemo Combo Before Surgery May Help Treat Early-Stage HER2-Positive Disease
Early results suggest that a combination of four medicines given BEFORE surgery to treat HER2-positive, early-stage breast cancer may be a good way to weaken and destroy breast cancer cells.
-
Herceptin and Tykerb Added to Chemo Before Surgery More Effective Than Adding Only One to Treat Early-Stage, HER2-Positive Disease
Giving both Herceptin and Tykerb with paclitaxel before surgery for HER2-positive breast cancer offered more benefits than Herceptin or Tykerb alone with paclitaxel new research shows.
-
Arimidex and Aromasin Equally Good at Reducing Recurrence Risk
A new study shows that Arimidex and Aromasin are equally good at reducing the risk of recurrence in postmenopausal women diagnosed with early-stage, hormone-receptor-positive breast cancer.
-
Avastin Added to Chemo Before Surgery Offers No Benefit
Research shows that adding Avastin to neoadjuvant chemotherapy doesn't seem to benefit women diagnosed with early-stage or locally-advanced breast cancer.
